Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment

Garima Mamgain; Praveen K Singh; Priyanka Patra; Manisha Naithani; Uttam K Nath

doi:10.4103/jfmpc.jfmpc_2432_21

Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment

J Family Med Prim Care. 2022 Aug;11(8):4151-4158. doi: 10.4103/jfmpc.jfmpc_2432_21. Epub 2022 Aug 30.

Authors

Garima Mamgain¹, Praveen K Singh², Priyanka Patra², Manisha Naithani², Uttam K Nath¹

Affiliations

¹ Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
² Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Abstract

The most common non-Hodgkin lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL). It accounts for roughly 30% of all cases of NHL affecting both nodal and extra nodal sites. There are molecular subtypes of DLBCL, germinal centre subtype (GCB), and activated B-cell (ABC), based on gene expression profiling (GEP), in accumulation to distinct morphological and clinicopathological subtypes. To prognosticate patients, the International Prognostication Index (IPI) and its variants are used. In ABC type DLBCL, limited stage disease is treated with a combination of abbreviated systemic chemotherapy (three cycles) and field radiation therapy. Although advanced stage disease is treated with a full course of chemotherapy as well as novel agents (Bortezomib, Ibrutinib, Lenalidomide). In this review study, we looked at the role of multiple aspects of genetic and microenvironment changes which have effects in DLBCL tumours.

Keywords: Activated B-cell; diffuse large B-cell lymphoma; germinal centre; rituximab.

Publication types

Review